Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) EBT Margin (2019 - 2025)

Historic EBT Margin for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to 154.5%.

  • BridgeBio Pharma's EBT Margin rose 58577300.0% to 154.5% in Q3 2025 from the same period last year, while for Sep 2025 it was 219.21%, marking a year-over-year decrease of 121200.0%. This contributed to the annual value of 244.34% for FY2024, which is 67776000.0% up from last year.
  • Per BridgeBio Pharma's latest filing, its EBT Margin stood at 154.5% for Q3 2025, which was up 58577300.0% from 164.3% recorded in Q2 2025.
  • BridgeBio Pharma's 5-year EBT Margin high stood at 21754.94% for Q4 2021, and its period low was 43350.3% during Q3 2022.
  • Over the past 5 years, BridgeBio Pharma's median EBT Margin value was 4526.28% (recorded in 2024), while the average stood at 7088.61%.
  • Data for BridgeBio Pharma's EBT Margin shows a peak YoY increase of 1348721500bps (in 2021) and a maximum YoY decrease of -408861700bps (in 2021) over the last 5 years.
  • BridgeBio Pharma's EBT Margin (Quarter) stood at 21754.94% in 2021, then crashed by -136bps to 7760.96% in 2022, then plummeted by -42bps to 11008.94% in 2023, then surged by 59bps to 4526.28% in 2024, then soared by 97bps to 154.5% in 2025.
  • Its EBT Margin was 154.5% in Q3 2025, compared to 164.3% in Q2 2025 and 121.0% in Q1 2025.